When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
It's more than worthwhile to keep up with what the big money is doing of late. While riding on the coattails of an investing legend may not lead to outperformance in any given year, it can be a subtle sign as to where relative value can be found, regardless of the type of market environment we find ourselves in.
Beyond analysts' top -and-bottom-line estimates for CVS Health (CVS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
On Jan. 30, Walgreens Boots Alliance, a leading pharmacy chain, announced that it was suspending its dividend program, which had been active for over 90 years. This longtime dividend payer is suffering under the weight of financial troubles and had previously resorted to decreasing its payouts.
CVS Health (CVS) reachead $55.69 at the closing of the latest trading day, reflecting a -1.17% change compared to its last close.
CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
For more than two years, the bulls have been running wild on Wall Street. Since 2023 began, the ageless Dow Jones Industrial Average, benchmark S&P 500 (^GSPC 0.72%), and growth-powered Nasdaq Composite have soared by 34%, 57%, and 88%, respectively, through the end of January 2025.
Volatility is plaguing Wall Street in light of President Donald Trump's tariffs.
Given that CVS Health's restructuring plan is described as enterprise-wide and ongoing, it is reasonable to expect significant charges in the fourth quarter.
CVS Health (CVS) closed the most recent trading day at $56.82, moving -0.14% from the previous trading session.
CVS Health stock has moved from one of the worst performers in the S&P 500 index in 2024 to the second-best performer this year. It has risen in the last six consecutive weeks and is hovering at its highest level since December 2.
Healthcare stocks are cheap. Earnings are expected to grow solidly, and RFK Jr. won't change that.